Can we really use ß-lactam/ß-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum ß-lactamase- producing bacteria?

Clinical Infectious Diseases

Volumn 54, Issue 2, 2012, Pages 175-177

  Perez, Federico ^a   Bonomo, Robert A ^a,b  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AVIBACTAM; CARBAPENEM; CEFTAROLINE; CEFTAZIDIME; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TAZOBACTAM;

ANTIBIOTIC SENSITIVITY; BLOODSTREAM INFECTION; DRUG MEGADOSE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; NOTE; PRIORITY JOURNAL; TREATMENT OUTCOME;

AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASES; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; MALE; PENICILLANIC ACID; PIPERACILLIN;

EID: 84555209226     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir793     Document Type: Note

References (12)

1. Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39:2206-12. (Pubitemid 32531482)
2. Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004; 39:31-7. (Pubitemid 38879546)
3. Paterson DL, Bonomo RA. Extendedspectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005; 18:657-86.
4. Diaz MA, Hernandez-Bello JR, Rodriguez-Bano J, et al. Diversity of Escherichia coli strains producing extended-spectrum betalactamases in Spain: second nationwide study. J Clin Microbiol 2010; 48:2840-5.
5. Oteo J, Cercenado E, Cuevas O, et al. AmpC beta-lactamases in Escherichia coli: emergence of CMY-2-producing virulent phylogroup D isolates belonging mainly to STs 57, 115, 354, 393, and 420, and phylogroup B2 isolates belonging to the international clone O25b-ST131. Diagn Microbiol Infect Dis 2010; 67:270-6.
6. Lodise TP Jr, Lomaestro B, Rodvold KA, Danziger LH, Drusano GL. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother 2004; 48:4718-24. (Pubitemid 39577677)
7. Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 2010; 23:160-201.
8. Pitout JD, Le P, Church DL, Gregson DB, Laupland KB. Antimicrobial susceptibility of well-characterised multiresistant CTXM-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/ tazobactam. Int J Antimicrob Agents 2008; 32:333-8.
9. Eagye KJ, Nicolau DP. Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals. Infect Control Hosp Epidemiol 2010; 31:485-90.
10. Sidjabat HE, Paterson DL, Qureshi ZA, et al. Clinical features and molecular epidemiology of CMY-type beta-lactamaseproducing Escherichia coli. Clin Infect Dis 2009; 48:739-44.
11. Bogaerts P, Hujer AM, Naas T, et al. Multicenter evaluation of a new DNA microarray for rapid detection of clinically relevant bla genes from {beta}-lactamresistant gram-negative bacteria. Antimicrob Agents Chemother 2011; 55:4457-60.
12. Livermore DM, Mushtaq S, Warner M, et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2011; 55:390-4.